Find clinical trials for Non-Hodgkin Lymphoma in Rochester, MN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near Rochester, MN, USA:
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Rochester, Minnesota, United States and 89 other locations
at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...
Phase 1, Phase 2
Rochester, Minnesota, United States and 12 other locations
patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...
Phase 1
Rochester, Minnesota, United States and 29 other locations
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...
Phase 1
Rochester, Minnesota, United States and 14 other locations
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non...
Phase 2
Rochester, Minnesota, United States and 7 other locations
monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...
Phase 2
Rochester, Minnesota, United States and 44 other locations
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...
Phase 2
Rochester, Minnesota, United States and 137 other locations
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Rochester, Minnesota, United States and 55 other locations
safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-...
Phase 2
Rochester, Minnesota, United States and 41 other locations
Clinical trials
Research sites
Resources
Legal